Bionano Genomics (BNGO) Current Deferred Revenue (2017 - 2026)

Bionano Genomics has disclosed Current Deferred Revenue across 10 years of filings, most recently posting $1.1 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $1.1 million, up 10.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 10.39% YoY), and the FY2025 annual result was $967000.0, down 14.27% from the prior year.
• Current Deferred Revenue came in at $1.1 million for Q1 2026 at Bionano Genomics, up from $967000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.2 million in Q3 2024 to a low of $783000.0 in Q4 2023.
• The 5-year median for Current Deferred Revenue is $1.1 million (2022), against an average of $1.0 million.
• Across the five-year window, Current Deferred Revenue jumped 267.77% in 2022 and decreased 17.12% in 2023, its largest moves.
• Bionano Genomics' Current Deferred Revenue stood at $871000.0 in 2022, then slipped by 10.1% to $783000.0 in 2023, then jumped by 44.06% to $1.1 million in 2024, then declined by 14.27% to $967000.0 in 2025, then gained by 16.44% to $1.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.1 million (Q1 2026), $967000.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.